Rigel Pharmaceuticals director sells 2,500 shares

RIGEL PHARMACEUTICALS INC director Ali-Jackson Kamil reported an open-market sale of 2,500 shares of Common Stock on May 26, 2026, at an average price of $29.17 per share.

Filing Impact

(Neutral)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

RIGEL PHARMACEUTICALS INC director Ali-Jackson Kamil reported an open-market sale of 2,500 shares of Common Stock on May 26, 2026, at an average price of $29.17 per share. Following the sale, the director directly holds 12,625 shares. The transaction was effected under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025.

Insider Trade Summary 10b5-1

Net Seller: 2,500 shares

Net Sell 1 txn

Insider Ali-Jackson Kamil

Role Director

Sold 2,500 shs ($73K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,500	$29.17	$73K

Holdings After Transaction: Common Stock — 12,625 shares (Direct)

Footnotes (1)

F1. The sale reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 7, 2025.

Key Figures

Shares sold: 2,500 shares Sale price: $29.17 per share Shares owned after sale: 12,625 shares +1 more

4 metrics

Shares sold 2,500 shares Open-market sale on May 26, 2026

Sale price $29.17 per share Average price for 2,500 shares sold

Shares owned after sale 12,625 shares Direct holdings following transaction

Net shares sold 2,500 shares Net-sell direction in transaction summary

Key Terms

Common Stock, open-market sale, Rule 10b5-1 trading plan

3 terms

Common Stock financial

"security_title: "Common Stock" in the non-derivative transaction"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

open-market sale financial

"transaction_action: "open-market sale" describing the transaction"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Rule 10b5-1 trading plan regulatory

"footnote states the sale was effected pursuant to a 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Ali-Jackson Kamil report at RIGL?

Director Ali-Jackson Kamil reported an open-market sale of Rigel Pharmaceuticals Common Stock. The Form 4 shows one transaction involving 2,500 shares sold on May 26, 2026, reflecting a routine insider disposition disclosed to the market.

How many Rigel Pharmaceuticals (RIGL) shares did the director sell?

The director sold 2,500 shares of Rigel Pharmaceuticals Common Stock. This single open-market transaction reduced the director’s holdings but left a remaining direct position of 12,625 shares, providing context for the scale of the sale relative to total ownership.

At what price were the RIGL shares sold in this Form 4 filing?

The reported 2,500 Rigel Pharmaceuticals shares were sold at an average price of $29.17 per share. This price reflects the execution level for the open-market transaction disclosed, giving investors a clear view of the sale’s per-share valuation.

How many Rigel Pharmaceuticals shares does Ali-Jackson Kamil own after the sale?

After the transaction, the director directly owns 12,625 shares of Rigel Pharmaceuticals Common Stock. This post-transaction holding, disclosed in the Form 4, helps investors understand the remaining equity stake following the 2,500-share open-market sale.

Was the RIGL insider sale made under a Rule 10b5-1 trading plan?

Yes. A footnote explains the sale was effected under a Rule 10b5-1 trading plan adopted on November 7, 2025. Such pre-arranged plans schedule trades in advance, which can reduce the significance of transaction timing for interpreting insider sentiment.

Is this RIGL Form 4 transaction a buy or sell activity?

This Form 4 reports a sell transaction. The filing classifies the event as an open-market sale of 2,500 shares of Common Stock, with the transaction direction identified as a sale and no corresponding purchases or option exercises reported.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 05/28/2026 - 04:19 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ali-Jackson Kamil

(Last)

(First)

(Middle)

RIGEL PHARMACEUTICALS, INC.

611 GATEWAY BLVD, SUITE 900

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RIGEL PHARMACEUTICALS INC [ RIGL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/26/2026		S⁽¹⁾		2,500	D	$29.17	12,625	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The sale reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 7, 2025.

	/s/ Raymond Furey (Attorney-in-Fact)	05/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR